Related Experiment Video
Updated: Jul 15, 2026

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas
Published on: February 28, 2019
REFCOR guidelines on the management of olfactory neuroblastoma: A formalized expert consensus
V Gorzkowski1, C Monnot2, C Castain3
1Service d'ORL-Chirurgie Cervico-Faciale, Université de Lorraine, CHRU Nancy, Service ORL, 54000 Nancy, France.
Introduction:
Olfactory neuroblastoma (ONB) is a rare malignant tumor of the sinonasal tract. The objective of this study is to present an evidence-based synthesis of the recommendations of the French Expert Network of Rare ENT Cancers (REFCOR), published in 2022, concerning the diagnostic and therapeutic management of ONB.
Method:
These recommendations result from a multidisciplinary consensus based on a critical analysis of the literature and feedback from expert centers within a structured process.
Results:
ONB accounts for 6% of sinonasal cancers, with no identified risk factors. Diagnosis is based on CT and MRI of the paranasal sinuses and skull base, together with systemic disease staging. Histopathological analysis requires specialized expertise, with Hyams histological grade as the main prognostic factor. The standard of care consists in surgical resection followed by adjuvant radiotherapy. Chemotherapy may be considered in high-grade or unresectable forms. Because of the risk of late recurrence, at least 20years' follow-up is recommended.
Conclusion:
The REFCOR guidelines aim to standardize diagnosis and treatment for ONB, but require completion by discussion in a specialized multidisciplinary tumor board.
Insights
Olfactory neuroblastoma (ONB) is a rare sinonasal cancer. New French guidelines standardize diagnosis and treatment, emphasizing surgery, radiotherapy, and long-term follow-up for this rare tumor.
Area of Science:
- Oncology
- Otorhinolaryngology (ENT)
- Rare Cancers
Background:
- Olfactory neuroblastoma (ONB) is a rare malignant tumor originating in the sinonasal tract.
- ONB represents 6% of all sinonasal cancers, with no established risk factors.
- Diagnosis involves CT and MRI for staging, with histopathology crucial for prognosis.
Purpose of the Study:
- To synthesize evidence-based recommendations from the French Expert Network of Rare ENT Cancers (REFCOR) for ONB management.
- To provide updated diagnostic and therapeutic guidelines for olfactory neuroblastoma.
- To establish a standardized approach for a rare sinonasal malignancy.
Main Methods:
- Multidisciplinary consensus development.
- Critical analysis of existing literature.
- Feedback from expert centers within a structured process.
Main Results:
- Histopathological grading (Hyams grade) is the primary prognostic indicator.
- Standard treatment involves surgical resection followed by adjuvant radiotherapy.
- Chemotherapy is an option for high-grade or unresectable ONB.
- Long-term follow-up (≥20 years) is recommended due to late recurrence risk.
Conclusions:
- REFCOR guidelines aim to standardize ONB diagnosis and treatment.
- Discussion in a specialized multidisciplinary tumor board is essential for optimal patient management.
- These recommendations support improved outcomes for patients with olfactory neuroblastoma.
Related Concept Videos
Standards of Care II
Standards of Care I
Olfactory Receptors: Location and Structure